Chris Boerner

Executive Vice President, Chief Commercialization Officer at Bristol-Myers Squibb Company

Chris Boerner

Chris Boerner

Executive Vice President, Chief Commercialization Officer at Bristol-Myers Squibb Company

Overview
RelSci Relationships

3579

Number of Boards

4

Birthday

1971

Age

49

Relationships
RelSci Relationships are individuals Chris Boerner likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former Chairman of the Board & Chief Executive Officer at Bristol-Myers Squibb Company

Relationship likelihood: Strong

Former Chief Executive Officer at Castlight Health, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Capital Health System, Inc.

Relationship likelihood: Strong

Former Senior Vice President-Managed Care & Customer Operations at Genentech, Inc.

Relationship likelihood: Strong

Director & Chief of Cardio Thoracic Section at Capital Health System, Inc.

Relationship likelihood: Strong

Former President & Chief Executive Officer at Foundation Medicine, Inc.

Relationship likelihood: Strong

Head of Therapeutics at 23andMe, Inc.

Relationship likelihood: Strong

Director of Level II Medical Center Neonatal Intensive Care Unit, Hopewell at Capital Health System, Inc.

Relationship likelihood: Strong

Medical Director-the Bristol-Myers Squibb Trauma Center at Capital Health System, Inc.

Relationship likelihood: Strong

Treasurer & Director at Capital Health System, Inc.

Relationship likelihood: Strong

Paths to Chris Boerner
Potential Connections via
Relationship Science
You
Chris Boerner
Executive Vice President, Chief Commercialization Officer at Bristol-Myers Squibb Company
Education
Ph.D. in Business Administration

The Walter A. Haas School of Business, also known as the Haas School of Business or simply Haas, is one of 14 schools and colleges at the University of California, Berkeley. The school runs a range of programs and is consistently ranked among the best in the country. Known for its small class size, academic rigor, and application selectivity, Haas is one of the most prestigious business schools in the world. It is the second oldest business school in the United States.

A.B. in Economics & History

The mission of Washington University in St. Louis is the promotion of learning — learning by students and by faculty. Teaching, the transmission of knowledge, is central to our mission, as is research, the creation of new knowledge. Faculty — composed of scholars, scientists, artists and members of the learned professions — serve society by teaching; by adding to the store of human art, creativity, understanding, and wisdom; and by providing direct services, such as health care. The university offers more than 90 programs and almost 1,500 courses leading to bachelor's, master's and doctoral degrees in a broad spectrum of traditional and interdisciplinary fields, with additional opportunities for minor concentrations and individualized programs.

Career History
Executive Vice President, Chief Commercialization Officer
2015 - Current

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Executive Vice President, Commercial
2010 - 2015

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Head-Marketing
2010 - 2010

Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Chris Boerner. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Chris Boerner's profile does not indicate a business or promotional relationship of any kind between RelSci and Chris Boerner.